Editorial illustration for DeepMind spinoff’s AI‑designed drugs enter human trials after AlphaFold 3
AI Drug Discovery Breakthrough Enters Human Trials
DeepMind spinoff’s AI‑designed drugs enter human trials after AlphaFold 3
The latest milestone for AI‑driven drug discovery arrived quietly on the clinical front: a DeepMind spinoff has moved its first computer‑crafted compounds into human testing. Isomorphic Labs, the biotech arm born from DeepMind’s protein‑folding work, says the new candidates were generated entirely by algorithms that map how proteins behave in the body. That claim matters because it follows a series of breakthroughs that have gradually broadened what machine‑learning models can predict about biology.
Earlier this year, the same teams rolled out a third‑generation version of their protein‑structure system, expanding its reach beyond static folds to include the surrounding genetic material that proteins interact with. The shift from isolated protein snapshots to a more holistic view of molecular choreography promises to tighten the link between computational sketches and real‑world therapeutics. With human volunteers now slated to receive these AI‑designed molecules, the industry watches to see whether the theoretical gains translate into measurable health outcomes.
"In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists' understanding of proteins even further. It moved beyond modeling proteins in isolation to predicting other important molecules, such as DNA and RNA, and their interactions with proteins. "This is exactly what you"
In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists' understanding of proteins even further. It moved beyond modeling proteins in isolation to predicting other important molecules, such as DNA and RNA, and their interactions with proteins. "This is exactly what you need for drug discovery: You need to see how a small molecule is going to bind to a drug, how strongly, and also what else it might bind to," Hassabis told WIRED at the time.
Since its release, the AlphaFold platform has been able to predict the structure of virtually all the 200 million proteins known to researchers and has been used by more than 2 million people from 190 countries. The breakthrough earned Hassabis and Jumper the Nobel Prize for chemistry in 2024, with the Nobel committee noting that AlphaFold has enabled a number of scientific applications, including a better understanding of antibiotic resistance and the creation of images of enzymes that can decompose plastic.
The upcoming human trials will be the first real‑world test of Isomorphic Labs’ AI‑designed compounds. Isomorphic Labs, a DeepMind spinoff, claims its Nobel‑Prize‑winning technology can produce safe, effective drugs, but the data remain limited to pre‑clinical work. Max Jaderberg’s comment at WIRED Health—“We’re gearing up to go into the clinic”—signals confidence, yet the outcome of the trials is still unknown.
AlphaFold 3, released in 2024, broadened the platform’s scope from isolated protein models to predictions of DNA, RNA and their protein interactions, a step that could streamline target identification. Whether this expanded modelling translates into clinical benefit, however, has yet to be demonstrated. The trials will reveal if the AI‑driven design pipeline can consistently generate candidates that meet regulatory safety standards and therapeutic efficacy.
Until those results are published, the promise of AI‑designed drugs remains provisional, and the scientific community will be watching closely for concrete evidence of benefit.
Further Reading
- Google DeepMind's Spinoff Company 'Very Close' to Human Trials for Its AI-Designed Drugs - Slashdot
- Isomorphic Labs has grand ambitions to 'solve all diseases' with AI - Fortune
- Isomorphic Labs prepares to launch trials for AI-designed drugs - Clinical Trials Arena
- Review of AlphaFold 3: Transformative Advances in Drug Design - PMC/NIH
- AlphaFold3: Revolutionizing drug discovery and development - Labiotech.eu
Related Reading
Browse all Google news →
Research & Benchmarks Hyperparameter Tuning Reaches 0.9617 Accuracy in 64.59 Seconds
Research & Benchmarks Pharma Cautious as AI Promises Faster Drug Discovery and Smarter Trials
Research & Benchmarks Google AI Advisors Let Users Probe Performance with Conversational “Why” Queries
Related Topic Gemini 3 Pro builds screenshot-to-code app in two prompts, fixes bugs
LLMs & Generative AI
Related Topic Gemini 3 Pro and GPT-5 stumble on graduate-level physics benchmark
LLMs & Generative AI
From Archives COALA paper defines agent memory types: procedural rules and semantic facts
From Archives Google DeepMind's Decoupled DiLoCo hits 88% goodput despite hardware failures
From Archives Google Cloud AI launches ReasoningBank with MaTTS memory-aware scaling
Policy & Regulation
From Archives Google unifies Gemini Enterprise Platform and Application in new release
Business & Startups
Common Questions Answered
How did AlphaFold 3 advance drug discovery capabilities?
AlphaFold 3 expanded protein modeling beyond isolated proteins to predict interactions between proteins, DNA, and RNA. This breakthrough allows scientists to better understand molecular interactions, which is crucial for designing more effective drug compounds.
What milestone has Isomorphic Labs achieved in AI-driven drug development?
Isomorphic Labs has moved its first computer-crafted drug compounds into human clinical trials, marking a significant step in AI-powered pharmaceutical research. These compounds were entirely generated by algorithmic models that map protein behaviors and molecular interactions.
What makes Isomorphic Labs' approach to drug discovery unique?
Isomorphic Labs uses advanced AI algorithms derived from DeepMind's protein-folding work to design drug compounds, moving beyond traditional drug discovery methods. Their approach leverages machine learning to predict molecular interactions and potential drug efficacy before traditional laboratory testing.